BEONE MEDICINES LTD-ADR (ONC) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ONC • US07725L1026

348.212 USD
-3.79 (-1.08%)
Last: Feb 5, 2026, 02:14 PM
Fundamental Rating

5

Overall ONC gets a fundamental rating of 5 out of 10. We evaluated ONC against 524 industry peers in the Biotechnology industry. ONC has an average financial health and profitability rating. ONC is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make ONC a good candidate for value and growth investing.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year ONC was profitable.
  • ONC had a positive operating cash flow in the past year.
  • In the past 5 years ONC always reported negative net income.
  • In the past 5 years ONC always reported negative operating cash flow.
ONC Yearly Net Income VS EBIT VS OCF VS FCFONC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -2B -4B -6B -8B -10B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -0.28%, ONC belongs to the top of the industry, outperforming 88.17% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -0.52%, ONC belongs to the top of the industry, outperforming 89.69% of the companies in the same industry.
  • ONC's Return On Invested Capital of 1.88% is amongst the best of the industry. ONC outperforms 89.69% of its industry peers.
Industry RankSector Rank
ROA -0.28%
ROE -0.52%
ROIC 1.88%
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ONC Yearly ROA, ROE, ROICONC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • Looking at the Operating Margin, with a value of 2.86%, ONC belongs to the top of the industry, outperforming 89.31% of the companies in the same industry.
  • ONC has a better Gross Margin (85.99%) than 88.55% of its industry peers.
  • In the last couple of years the Gross Margin of ONC has remained more or less at the same level.
Industry RankSector Rank
OM 2.86%
PM (TTM) N/A
GM 85.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
ONC Yearly Profit, Operating, Gross MarginsONC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ONC is destroying value.
  • Compared to 1 year ago, ONC has more shares outstanding
  • The number of shares outstanding for ONC has been increased compared to 5 years ago.
  • The debt/assets ratio for ONC is higher compared to a year ago.
ONC Yearly Shares OutstandingONC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ONC Yearly Total Debt VS Total AssetsONC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.2 Solvency

  • An Altman-Z score of 6.21 indicates that ONC is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ONC (6.21) is better than 75.95% of its industry peers.
  • The Debt to FCF ratio of ONC is 2.51, which is a good value as it means it would take ONC, 2.51 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of ONC (2.51) is better than 93.32% of its industry peers.
  • A Debt/Equity ratio of 0.23 indicates that ONC is not too dependend on debt financing.
  • The Debt to Equity ratio of ONC (0.23) is worse than 66.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 2.51
Altman-Z 6.21
ROIC/WACC0.39
WACC4.8%
ONC Yearly LT Debt VS Equity VS FCFONC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B

2.3 Liquidity

  • ONC has a Current Ratio of 2.40. This indicates that ONC is financially healthy and has no problem in meeting its short term obligations.
  • ONC's Current ratio of 2.40 is on the low side compared to the rest of the industry. ONC is outperformed by 71.37% of its industry peers.
  • A Quick Ratio of 2.17 indicates that ONC has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.17, ONC is doing worse than 71.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.17
ONC Yearly Current Assets VS Current LiabilitesONC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • ONC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 215.42%, which is quite impressive.
  • Looking at the last year, ONC shows a very strong growth in Revenue. The Revenue has grown by 50.62%.
  • ONC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.91% yearly.
EPS 1Y (TTM)215.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%188.84%
Revenue 1Y (TTM)50.62%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.84%

3.2 Future

  • Based on estimates for the next years, ONC will show a very strong growth in Earnings Per Share. The EPS will grow by 99.00% on average per year.
  • Based on estimates for the next years, ONC will show a quite strong growth in Revenue. The Revenue will grow by 19.26% on average per year.
EPS Next Y146.71%
EPS Next 2Y71.19%
EPS Next 3Y49.35%
EPS Next 5Y99%
Revenue Next Year41.33%
Revenue Next 2Y31.33%
Revenue Next 3Y25.89%
Revenue Next 5Y19.26%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ONC Yearly Revenue VS EstimatesONC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 20B 40B 60B 80B
ONC Yearly EPS VS EstimatesONC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1K 2K 3K

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 5.35, the valuation of ONC can be described as very cheap.
  • Compared to the rest of the industry, the Price/Earnings ratio of ONC indicates a rather cheap valuation: ONC is cheaper than 99.43% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 28.25. ONC is valued rather cheaply when compared to this.
  • ONC is valuated quite expensively with a Price/Forward Earnings ratio of 51.47.
  • Based on the Price/Forward Earnings ratio, ONC is valued cheaper than 90.08% of the companies in the same industry.
  • ONC is valuated expensively when we compare the Price/Forward Earnings ratio to 27.50, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 5.35
Fwd PE 51.47
ONC Price Earnings VS Forward Price EarningsONC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 91.98% of the companies in the same industry are more expensive than ONC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 80.6
EV/EBITDA N/A
ONC Per share dataONC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ONC's earnings are expected to grow with 49.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y71.19%
EPS Next 3Y49.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ONC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BEONE MEDICINES LTD-ADR

NASDAQ:ONC (2/5/2026, 2:14:23 PM)

348.212

-3.79 (-1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)04-15
Inst Owners42.98%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change-4.66%
Market Cap38.53B
Revenue(TTM)35.67B
Net Income(TTM)-153.00M
Analysts82.5
Price Target347.71 (-0.14%)
Short Float %16.99%
Short Ratio4.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.55
Dividend Growth(5Y)N/A
DP-360.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)590.84%
Min EPS beat(2)-5.45%
Max EPS beat(2)1187.13%
EPS beat(4)3
Avg EPS beat(4)1523.03%
Min EPS beat(4)-5.45%
Max EPS beat(4)3109.85%
EPS beat(8)3
Avg EPS beat(8)516.07%
EPS beat(12)4
Avg EPS beat(12)343.82%
EPS beat(16)5
Avg EPS beat(16)253.79%
Revenue beat(2)1
Avg Revenue beat(2)2.46%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)6.29%
Revenue beat(4)2
Avg Revenue beat(4)2.29%
Min Revenue beat(4)-1.36%
Max Revenue beat(4)6.29%
Revenue beat(8)6
Avg Revenue beat(8)8.35%
Revenue beat(12)10
Avg Revenue beat(12)12.39%
Revenue beat(16)13
Avg Revenue beat(16)10.75%
PT rev (1m)3.74%
PT rev (3m)5.3%
EPS NQ rev (1m)-13.89%
EPS NQ rev (3m)143.38%
EPS NY rev (1m)19.64%
EPS NY rev (3m)60.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.76%
Valuation
Industry RankSector Rank
PE 5.35
Fwd PE 51.47
P/S 7.5
P/FCF 80.6
P/OCF 54.99
P/B 9.12
P/tB 9.52
EV/EBITDA N/A
EPS(TTM)65.11
EY18.7%
EPS(NY)6.77
Fwd EY1.94%
FCF(TTM)4.32
FCFY1.24%
OCF(TTM)6.33
OCFY1.82%
SpS46.44
BVpS38.19
TBVpS36.58
PEG (NY)0.04
PEG (5Y)N/A
Graham Number236.53
Profitability
Industry RankSector Rank
ROA -0.28%
ROE -0.52%
ROCE 2.73%
ROIC 1.88%
ROICexc 5.89%
ROICexgc 6.47%
OM 2.86%
PM (TTM) N/A
GM 85.99%
FCFM 9.3%
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 2.51
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 4.33%
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 2.17
Altman-Z 6.21
F-Score7
WACC4.8%
ROIC/WACC0.39
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)20.18%
Cap/Sales(5y)27.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)215.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%188.84%
EPS Next Y146.71%
EPS Next 2Y71.19%
EPS Next 3Y49.35%
EPS Next 5Y99%
Revenue 1Y (TTM)50.62%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.84%
Revenue Next Year41.33%
Revenue Next 2Y31.33%
Revenue Next 3Y25.89%
Revenue Next 5Y19.26%
EBIT growth 1Y115.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year206.46%
EBIT Next 3Y69.73%
EBIT Next 5Y60.54%
FCF growth 1Y131.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y172.14%
OCF growth 3YN/A
OCF growth 5YN/A

BEONE MEDICINES LTD-ADR / ONC FAQ

What is the ChartMill fundamental rating of BEONE MEDICINES LTD-ADR (ONC) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ONC.


What is the valuation status for ONC stock?

ChartMill assigns a valuation rating of 7 / 10 to BEONE MEDICINES LTD-ADR (ONC). This can be considered as Undervalued.


How profitable is BEONE MEDICINES LTD-ADR (ONC) stock?

BEONE MEDICINES LTD-ADR (ONC) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for ONC stock?

The Price/Earnings (PE) ratio for BEONE MEDICINES LTD-ADR (ONC) is 5.35 and the Price/Book (PB) ratio is 9.12.


Can you provide the dividend sustainability for ONC stock?

The dividend rating of BEONE MEDICINES LTD-ADR (ONC) is 0 / 10 and the dividend payout ratio is -360.44%.